Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Novo Nordisk said on Friday the US Food and Drug Administration has granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver ...

The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent ...